About: Fibrinolytic Therapy for Refractory COVID‐19 Acute Respiratory Distress Syndrome: Scientific Rationale and Review

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Fibrinolytic Therapy for Refractory COVID‐19 Acute Respiratory Distress Syndrome: Scientific Rationale and Review Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Fibrinolytic Therapy for Refractory COVID‐19 Acute Respiratory Distress Syndrome: Scientific Rationale and Review
Creator	Moore, K Barrett, Christopher Daniel, \| Burke, John Mcintyre, Robert Michael, \| Moore, Ernest Moore, Hunter Peter, \| Veress, Livia Yaffe, B Yaffe, Michael Apgar, Joshua Correspondence, Ernest Fei, \| Liptzin, Deborah Moore, Phd, Hua Sauaia, Angela Talmor, S
Source	Medline; PMC; WHO
abstract	The COVID‐19 pandemic has caused respiratory failure and associated mortality in numbers that have overwhelmed global health systems. Thrombotic coagulopathy is present in nearly three‐quarters of COVID‐19 patients admitted to the intensive care unit, and both the clinical picture and pathologic findings are consistent with microvascular occlusive phenomena being a major contributor to their unique form of respiratory failure. Numerous studies are ongoing focusing on anti‐cytokine therapies, antibiotics and anti‐viral agents, but none to‐date have focused on treating the underlying thrombotic coagulopathy in an effort to improve respiratory failure in COVID‐19. There is animal data and a previous human trial demonstrating a survival advantage with fibrinolytic therapy to treat ARDS. Here we review the extant and emerging literature on the relationship between thrombotic coagulopathy and pulmonary failure in the context of COVID‐19 and present the scientific rationale for consideration of targeting the coagulation and fibrinolytic systems to improve pulmonary function in these patients.
has issue date	2020-04-28(xsd:dateTime)
bibo:doi	10.1002/rth2.12357
bibo:pmid	32542213
has license	cc-by-nc-nd
sha1sum (hex)	8bda5b4dd18a88da6be9ea63366784f4341794e4
schema:url	https://doi.org/10.1002/rth2.12357
resource representing a document's title	Fibrinolytic Therapy for Refractory COVID‐19 Acute Respiratory Distress Syndrome: Scientific Rationale and Review
has PubMed Central identifier	PMC7267116
has PubMed identifier	32542213
schema:publication	Res Pract Thromb Haemost
resource representing a document's body	covid:8bda5b4dd18a88da6be9ea63366784f4341794e4#body_text
is schema:about of	named entity 'caused' named entity 'respiratory failure' named entity 'HAVE' named entity 'GLOBAL HEALTH' named entity 'RESPIRATORY FAILURE' covid:arg/8bda5b4dd18a88da6be9ea63366784f4341794e4 named entity 'health systems' named entity 'respiratory failure' named entity 'acute respiratory distress syndrome' named entity 'tissue plasminogen activator' named entity 'respiratory failure' named entity 'viral entry' named entity 'pulmonary embolism' named entity 'hemorrhage' named entity 'tocilizumab' named entity 'COVID' named entity 'ARDS' named entity 'remdesivir' named entity 'Pulmonary Embolism' named entity 'interleukin-6' named entity 'TMPRSS2' named entity 'respiratory failure' named entity 'fibrinolysis' named entity 't-PA' named entity 'Coronavirus disease 2019' named entity 'microthrombi' named entity 'arginine' named entity 'fibrin' named entity 'platelets' named entity 'D-dimer' named entity 'fibrin' named entity 'COVID' named entity 'COVID' named entity 'chloroquine' named entity 'lung compliance' named entity 'ARDS' named entity 'thrombi' named entity 'hydroxychloroquine' named entity 'antibiotics' named entity 'COVID-19' named entity 'intensive care unit' named entity 'COVID' named entity 'tissue factor' named entity 'endotoxemia' named entity 'bronchoscopy' named entity 'respiratory failure' named entity 'hemodynamic' named entity 'thrombosis' named entity 'COVID-19' named entity 'medically refractory' named entity 'arginine' named entity 'thrombotic' named entity 'epithelial cells' named entity 'receptor binding domain' named entity 'COVID-19' named entity 'clinicaltrials.gov' named entity 'sepsis' named entity 'intensive care' named entity 'pulmonary vascular' named entity 'critically ill patients' named entity 'enzyme' named entity 'Plasmin'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software